Johnson & Johnson 4Q Revenues: $20.2 billion (+12%) 4Q Loss: $10.7 billion (earnings were $3.8 billion 4Q16) FY Revenues: $76.5 billion (+6%) FY Earnings: $1.3 billion (-92%) Comments: Worldwide Pharmaceutical sales were $36.3 billion for the year, up 8%. Domestic sales increased 7% and international sales increased 11%. Growth in new products include DARZALEX for the treatment of multiple myeloma, with $1.2 billion in sales, IMBRUVICA, to treat certain B-cell malignancies, with $1.9 bi...